Among patients with HCV genotype 2 infection , an SVR24 was achieved by 83 % , 83 % , and 63 % of those in the daclatasvir 12-week group , the daclatasvir 16-week group , or the placebo group , respectively ; among patients with HCV genotype 3 infection , an SVR24 was achieved by 69 % , 67 % , and 59 % of patients in these groups , respectively .